Related Experiment Videos
Prenatal diagnosis in Rett syndrome
J Armstrong1, E Aibar, M Pineda
1Genetics Section, University Hospital Sant Joan de Déu, Av. Sant Joan de Déu 2, E-89050 Esplugues, Barcelona, Spain.
Fetal Diagnosis and Therapy
|June 18, 2002
Summary
Prenatal diagnosis for Rett syndrome (RTT) is valuable for families with identified MECP2 gene mutations. It helps reduce recurrence risk in new pregnancies, especially when germline mosaicism is a possibility.
Area of Science:
- Genetics
- Neurodevelopmental Disorders
- Molecular Biology
Background:
- Rett syndrome (RTT) is a rare X-linked neurodevelopmental disorder primarily caused by de novo mutations in the MECP2 gene.
- While mostly sporadic, familial cases of RTT exist, necessitating genetic counseling and diagnostic options for affected families.
Purpose of the Study:
- To evaluate the utility of prenatal diagnosis for Rett syndrome in families with identified MECP2 mutations.
- To assess the role of prenatal testing in managing recurrence risk in pregnancies following an RTT diagnosis.
Main Methods:
- DNA analysis using Single-Strand Conformation Polymorphism (SSCP)/Heteroduplex (HD) analysis and sequencing to detect MECP2 mutations.
- Prenatal diagnosis performed on fetal samples (amniotic fluid or chorionic villus biopsy) using established mutation analysis methods.
Main Results:
- Three distinct heterozygous MECP2 mutations (1061del96bp, 473C-->T, 763C-->T) were identified in affected patients.
- Maternal DNA analysis ruled out carrier status in two mothers, and prenatal testing confirmed the absence of the mutation in the fetuses of the three families studied.
Conclusions:
- Prenatal diagnosis for Rett syndrome is beneficial for families with a previously identified MECP2 mutation.
- It helps mitigate recurrence risks associated with potential germline mosaicism or asymptomatic maternal carriers, offering reassurance for future pregnancies.